Holen Sie sich die Stockscreener-App
117.59
3.34%
-4.06
Handel nachbörslich:
117.59
Schlusskurs vom Vortag:
$121.65
Offen:
$122.08
24-Stunden-Volumen:
645.53K
Relative Volume:
0.97
Marktkapitalisierung:
$7.27B
Einnahmen:
$3.91B
Nettoeinkommen (Verlust:
$394.92M
KGV:
-74.90
EPS:
-1.57
Netto-Cashflow:
$1.02B
1W Leistung:
-7.50%
1M Leistung:
+2.22%
6M Leistung:
+7.89%
1J Leistung:
-2.46%
1-Tages-Spanne:
$117.46
$122.88
1-Wochen-Bereich:
$117.46
$128.99
52-Wochen-Spanne:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| JAZZ | 117.59 | 7.27B | 3.91B | 394.92M | 1.02B | -1.57 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals: High Uncertainty, Low Risk (undefined:JAZZ) - Seeking Alpha
Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $162.00 Price Target at Robert W. Baird - MarketBeat
Victory Capital Management Inc. Increases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Los Angeles Capital Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Plc: Its Efforts Towards Zepzelca Frontline Therapy Expansion & Other Major Drivers - Smartkarma
KBC Group NV Has $25.44 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Principal Financial Group Inc. Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Idiopathic Hypersomnia Treatment Market will experience - openPR
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock? - Yahoo Finance
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Jazz Pharmaceuticals' EVP Neena Patil sells $456,617 in shares By Investing.com - Investing.com Australia
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) PT at $175.00 - MarketBeat
Jazz Pharmaceuticals' EVP Neena Patil sells $456,617 in shares - Investing.com
Jazz (JAZZ) Upgraded to Buy: Here's Why - Yahoo Finance
JAZZ or CTLT: Which Is the Better Value Stock Right Now? - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Kovack Advisors Inc. - MarketBeat
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High? - Yahoo Finance
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? - Yahoo Finance
American Assets Inc. Invests $557,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2024 - Marketscreener.com
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
28,693 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by CWA Asset Management Group LLC - MarketBeat
Amalgamated Bank Sells 9,681 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Philip James Wealth Mangement LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2024 Earnings Call Transcript - Insider Monkey
Van ECK Associates Corp Increases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Quarterly 10-Q Report - Quartzy
Jazz Pharma revenues rise 9% in third quarter | Pharmaceutical | The Pharmaletter - The Pharma Letter
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View - Nasdaq
Jazz Pharmaceuticals' (JAZZ) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Robeco Institutional Asset Management B.V. Sells 19,161 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Jazz Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Jazz Hits Record Q3 Revenue with Strong Growth in Sleep Portfolio - Sleep Review
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? - Benzinga
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates - Yahoo Canada Finance
Jazz: Q3 Earnings Snapshot - San Antonio Express-News
Jazz Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results - PR Newswire
Insider Decision: Bruce C Cozadd Offloads $110K Worth Of Jazz Pharmaceuticals Stock - Benzinga
Jazz Pharmaceuticals Iberia Recognized as One of the 100 Best Companies To Work for in Spain - CSRwire.com
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics - Yahoo Finance
Private Advisor Group LLC Acquires 5,437 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz - Sleep Review
US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Yahoo Finance
International Assets Investment Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):